Comparing Phathom Pharmaceuticals (NASDAQ:PHAT) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Neuphoria Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-25.98%	-18.39%
Phathom Pharmaceuticals	-126.35%	N/A	-68.66%

Volatility & Risk

Neuphoria Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Earnings & Valuation

This table compares Neuphoria Therapeutics and Phathom Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	1.63	-$370,000.00	($4.42)	-1.07
Phathom Pharmaceuticals	$175.11 million	5.69	-$221.25 million	($3.06)	-4.13

Neuphoria Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neuphoria Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	1	2	0	2.25
Phathom Pharmaceuticals	1	1	6	1	2.78

Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 344.92%. Phathom Pharmaceuticals has a consensus target price of $22.50, indicating a potential upside of 78.01%. Given Neuphoria Therapeutics’ higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Phathom Pharmaceuticals.

Summary

Phathom Pharmaceuticals beats Neuphoria Therapeutics on 10 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.